2016-03-04T00:00:00.000-05:00
complete loss,-0.418055
vast majority,-0.319711
drug developers,-0.40708
fourth-quarter earnings report,-0.503456
Wall Street,0.331972
biosimilar drugs,-0.540254
substantially better sales,0.754969
top-line sales,-0.422997
money-losing stocks,-0.752868
multiple sclerosis,-0.586335
Teva Pharmaceutical,-0.510249
disclosure policy,-0.438396
multiple sclerosis juggernaut,-0.510249
investor sentiment,-0.503456
narrower loss,-0.422997
Motley Fool,-0.403014
near-term cash concerns,-0.543644
biopharmaceutical company,-0.540254
Drug Administration,-0.449453
substantial jump,-0.389962
stock market,-0.461667
fourth-quarter earnings release,-0.230503
fourth-quarter report,-0.418055
Net loss,-0.565089
therapies Momenta,-0.377773
weaker-than-expected fourth-quarter earnings,-0.366979
autoimmune diseases,-0.540254
prior-year quarter,-0.237922
Momenta,0.185386
unmistakable problem,-0.230503
best-selling drug,0.302561
0.31-per-share loss,-0.483474
better investors,0.52021
generic application,-0.607179
National Cancer Institute,-0.561001
current annual sales,-0.377773
big way,0.584623
generic multiple sclerosis,-0.662421
Foolish newsletter services,-0.240471
